Bavencio savings card: as little as $0 a treatment with commercial insurance

Bavencio is given by a doctor or nurse and billed by the clinic, not a pharmacy. Your care team and your insurance decide which product you get, so ask them what you’d pay.

How to pay the least

Given by your care team

Billed by the clinic

Bavencio is given by a doctor or nurse, not picked up at a pharmacy.

Ask your care team or your plan what you’d pay before your visit.

Compare every option

Brand nameBavencio

Authorized genericavelumab

Regular genericavelumab

What you’d pay

Cash priceAsk the pharmacy

Not soldThere isn’t one

Not soldAsk the pharmacy

Same as Bavencio?

The original

–

Brand nameThe maker’s card

CoverOne Co-Pay Assistance Program

Savings card from EMD Serono

No insuranceNeeds insuranceNo cash price listed.

Insurance · as little as $0 a treatment

The card takes up to $30,000 a year off your co-pay.

In the maker’s words

“Enrolled patients may be eligible to pay as little as a $0 co-pay for each treatment for Bavencio, up to a maximum of $30,000 per year.”

From the maker’s offer on coverone.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Authorized genericNot sold

There isn’t one. An authorized generic is Bavencio itself, from the same company, sold without the brand name, and usually for less. For now Bavencio is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

Bavencio is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

BAVENCIO is a programmed death ligand-1 (PD-L1) blocking antibody indicated for:

Merkel Cell Carcinoma (MCC)

Adults and pediatric patients 12 years and older with metastatic MCC.

Urothelial Carcinoma (UC)

Maintenance treatment of patients with locally advanced or metastatic UC that has not progressed with first-line platinum-containing chemotherapy.
Patients with locally advanced or metastatic UC who:
- Have disease progression during or following platinum-containing chemotherapy.
- Have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

Renal Cell Carcinoma (RCC)

First-line treatment, in combination with axitinib, of patients with advanced RCC.

Source: the FDA label for Bavencio (EMD Serono, Inc.), September 22, 2026. Full label on DailyMed

Good to know

“Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.
Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to the clinic’s billing office.
Don’t stop or change a medicine without talking to your pharmacist or prescriber.

Prices checked November 2, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/bavencio/